DELFI Diagnostics (“DNA EvaLuation of Fragments for early Interception”) is developing next-generation, blood-based cancer detection tests that are accurate, accessible and deliver a new way to detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics. Our science is based on fragmentomics, the discovery that cancer cells are more disorganized than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. We combine advanced machine-learning with whole-genome sequencing data to accurately compare an individual’s cfDNA fragments against populations with and without cancer. The DELFI platform uses these millions of data points to reliably identify individuals who may have lung cancer, including early stage disease.
DELFI’s first product is a lung cancer detection test for screen-eligible individuals. Lung cancer remains the top cancer killer in the United States, with nearly 140,000 people dying from the disease each year. Low-dose CT scans have proven effective in detecting disease, yet 94% of eligible adults do not receive them. The DELFI test has a 99.7% negative predictive value, meaning that individuals who do not show signs of disease are not likely to have lung cancer found by LDCT.
This will close in 0 seconds
